| __timestamp | Celldex Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 3243000 |
| Thursday, January 1, 2015 | 4011000 | 2472000 |
| Friday, January 1, 2016 | 102026000 | 2548000 |
| Sunday, January 1, 2017 | 96171000 | 19623000 |
| Monday, January 1, 2018 | 66449000 | 30421000 |
| Tuesday, January 1, 2019 | 42672000 | 32793999 |
| Wednesday, January 1, 2020 | 42534000 | 28304000 |
| Friday, January 1, 2021 | 3068000 | 620000 |
| Saturday, January 1, 2022 | 1400000 | 755000 |
| Sunday, January 1, 2023 | 3008000 | 1322000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial health is crucial. Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Celldex's cost of revenue fluctuated significantly, peaking in 2016 with a staggering 102 million, before plummeting to just 1.4 million in 2022. This represents a dramatic 99% decrease, highlighting the volatility in their operational costs. Meanwhile, Viridian's cost of revenue, though lower, showed a more stable trajectory, with a notable peak in 2019 at 32.8 million. By 2023, both companies had reduced their costs, with Viridian's expenses dropping by 96% from its peak. This data underscores the unpredictable nature of biotech investments and the importance of strategic financial management.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Pfizer Inc. and Viridian Therapeutics, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Amgen Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Analyzing Cost of Revenue: Evotec SE and Viridian Therapeutics, Inc.